Previous 10 | Next 10 |
2023-11-14 13:27:15 ET Predictive Oncology Inc. (POAI) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Conference Call Participants Present...
Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable dr...
2023-11-14 07:19:46 ET More on Predictive Oncology Financial information for Predictive Oncology For further details see: Predictive Oncology GAAP EPS of -$0.78, revenue of $0.72M
PITTSBURGH, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate onco...
Predictive Oncology Inc. (POAI) is expected to report for Q1 2024
2023-11-13 09:41:06 ET Major earnings expected before the bell on Tuesday include: Canadian Solar ( CSIQ ) The Home Depot ( HD ) Sea ( SE ) Vodafone Group Public ( VOD ) Workhorse Group ( WKHS ) For further details see: Notable earnings be...
Predictive Oncology (NASDAQ: POAI) , a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, has completed a multiyear study through a partnership with UPMC Magee-Womens Hospital. The study was focused on evaluating the use of AI in building multiomic machine...
PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital. The objective of the study was to evaluate the use of AI to build mu...
Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Pr...
EAGAN, Minn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) ...
News, Short Squeeze, Breakout and More Instantly...
Predictive Oncology Inc. Company Name:
POAI Stock Symbol:
NASDAQ Market:
Predictive Oncology Inc. Website:
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (“GPCRs”). GPCRs are cell surface membrane receptors believed to play a...
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annu...
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. More closely mimicking human tissue architecture than traditional 2D a...